Biotechnology
Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight loss drugs at the White House, Nov. 6, 2025. Andrew Caballero-Reynolds | Afp | Getty Images Novo Nordisk entered 2026 with the momentum of a historic year in more ways than one — but recent weeks have delivered more […]
Read More
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
Novo Nordisk CEO Mike Doustdar. CNBC Novo Nordisk CEO Mike Doustdar on Wednesday said the company is aiming to capture around 15 million new patients, at least initially, when Medicare starts covering obesity treatments for the first time later this year. Around 67 million Americans are covered by Medicare, but “when you take a look […]
Read More
Moderna says FDA refuses to review its application for experimental flu shot
A researcher works in the lab at the Moderna Inc. headquarters in Cambridge, Massachusetts, US, on Tuesday, March 26, 2024. Adam Glanzman | Bloomberg | Getty Images The Food and Drug Administration has refused to start a review of Moderna‘s application for its experimental flu shot, the company announced Tuesday, in another sign of the […]
Read More
CVS tops quarterly estimates, reaffirms profit outlook as turnaround plan takes effect
A pedestrian walks by a CVS store in Greenbrae, California, on July 31, 2025. Justin Sullivan | Getty Images CVS Health on Tuesday reported fourth-quarter earnings and revenue that beat estimates and reaffirmed the 2026 profit guidance that impressed investors, signaling steady progress in the health-care giant’s turnaround plan. “’24 was a tough year for […]
Read More
FDA says Novo Nordisk’s TV ad for obesity pill includes ‘false or misleading’ claims
Still life of the new Wegovy semaglutide tablets on a white background. Its a prescription medicine used with a reduced calorie diet and .and physical activity. Michael Siluk | Universal Images Group | Getty Images The Food and Drug Administration said Novo Nordisk‘s TV advertisement for its newly launched Wegovy pill for obesity included “false […]
Read More
Novo Nordisk sues Hims & Hers over cheaper copycat versions of Wegovy pill, injections
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, February 4, 2026. Tom Little | Reuters Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in […]
Read More
The White House is launching direct-to-consumer drug site Trump Rx. Here’s what to know
U.S. President Donald Trump makes an announcement from the Oval Office at the White House in Washington, D.C., U.S. Nov. 6, 2025. Jonathan Ernst | Reuters President Donald Trump on Thursday is slated to announce the launch of TrumpRx – a direct-to-consumer website that is key to his administration’s efforts to lower prescription drug costs […]
Read More
Eli Lilly’s GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
The Eli Lilly and Novo Nordisk logos. Mike Blake | Tom Little | Reuters It’s a tale of two drugmakers in the red-hot obesity drug market. Both Novo Nordisk and Eli Lilly are grappling with lower prices in the U.S., but their 2026 outlooks are diverging sharply: While Novo is bracing for a sales decline, […]
Read More
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant […]
Read More
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck on Tuesday reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But the company posted a modest 2026 outlook that fell short of Wall Street’s expectations as it prepares for a few drugs to lose patent protection later this year and face generic […]
Read More